Multiple studies have reported that inhibiting CD36 or SCD1 in prostate cancer or other tumors can promote antitumor immunity, increase CD8+‐T cell infiltration, and reduce the invasion of immunosuppressive cells such as Treg cells and TAMs.[16, 17, 18, 19, 32, 33] As shown in Figure 6A,C–E, in the PBS group and HA‐TR group of LFD‐fed mice, the tumor tissues were infiltrated with mainly CD4+ T cells, but the ratio of CD8+/CD4+ T cells gradually increased in the monotherapy and combination groups. This evidence concerns the gene CD8A and prostate carcinoma.